BioXell fails to find buyers for remaining assets ahead of Cosmo acquisition
This article was originally published in Scrip
Executive Summary
BioXell, which is in the process of being acquired by fellow Italian firm Cosmo Pharmaceuticals, has ended efforts to divest its remaining technology assets.